What keeps nagging at me: half the time BPC-157 and TB-500 end up used in combination anyway, since people stack the two for injury recovery. So you could almost argue for funding one trial that examines them side by side rather than choosing between them. Then again, keep them apart and you preserve the tidy "here is precisely what we tested" narrative; combine them and that is gone.
The paper trail favours BPC-157, mind you. It is the stomach-derived fragment, and for tendons and gut healing the animal data is genuinely respectable — not spectacular, but solid enough that a lab would not laugh you out of the room if you submitted a real proposal. TB-500 sits closer to thymosin, tied to wound healing and cell migration, and truthfully much of what gets said about it online amounts to vibes inherited from how BPC-157 is regarded.
Going with BPC-157 would probably be the straightforward move. Should such a campaign actually succeed and bankroll a real trial, TB-500 could come next, since the same audience is already in place and already primed for it.
Several 100mil - bil dollars is what something like this costs, and I know it. Viewed on a worldscale, it could be within reach.
The side effect: a premium price is no longer something these peptides can command. Open licencing forces competitive pricing.
and even more to the point, regulated Quality
The paper trail favours BPC-157, mind you. It is the stomach-derived fragment, and for tendons and gut healing the animal data is genuinely respectable — not spectacular, but solid enough that a lab would not laugh you out of the room if you submitted a real proposal. TB-500 sits closer to thymosin, tied to wound healing and cell migration, and truthfully much of what gets said about it online amounts to vibes inherited from how BPC-157 is regarded.
Going with BPC-157 would probably be the straightforward move. Should such a campaign actually succeed and bankroll a real trial, TB-500 could come next, since the same audience is already in place and already primed for it.
Several 100mil - bil dollars is what something like this costs, and I know it. Viewed on a worldscale, it could be within reach.
The side effect: a premium price is no longer something these peptides can command. Open licencing forces competitive pricing.
and even more to the point, regulated Quality